Intraperitoneal nebulization of thermosensitive hydrogels for the controlled release of chemotherapeutics and biopharmaceuticals to treat peritoneal carcinomatosis Ghent University
Yearly, about 150000 people develop peritoneal carcinomatosis (PC) in Europe alone. PC is characterized by the spread of numerous small tumor nodules in the peritoneal cavity. After initial surgery, where as many tumor nodules are removed as possible, the patients receive the intraperitoneal injection of chemotherapeutics such as cisplatin. The prognosis of this patients is however poor, with a median survival of 8 to 12 months. Currently, ...